HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation

The diversity of human leukocyte antigens (HLAs) enables the presentation of immense repertoires of peptides, including tumor-associated antigens (TAAs). As a surrogate for immunopeptidome diversity, the HLA evolutionary divergence (HED) between individual HLA alleles might directly define the abili...

Full description

Bibliographic Details
Main Authors: Malte Roerden, Annika Nelde, Jonas S. Heitmann, Reinhild Klein, Hans-Georg Rammensee, Wolfgang A. Bethge, Juliane S. Walz
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
AML
Online Access:https://www.mdpi.com/2072-6694/12/7/1835